Quality of anti-malarial drugs provided by public and private healthcare providers in south-east Nigeria
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: There is little existing knowledge about actual quality of drugs provided by different providers in Nigeria and in many sub-Saharan African countries. Such information is important for improving malaria treatment that will help in the development and implementation of actions designed to improve the quality of treatment. The objective of the study was to determine the quality of drugs used for the treatment of malaria in a broad spectrum of public and private healthcare providers. METHODS: The study was undertaken in six towns (three urban and three rural) in Anambra state, south-east Nigeria. Anti-malarials (225 samples), which included artesunate, dihydroartemisinin, sulphadoxine-pyrimethamine (SP), quinine, and chloroquine, were either purchased or collected from randomly selected providers. The quality of these drugs was assessed by laboratory analysis of the dissolution profile using published pharmacopoeial monograms and measuring the amount of active ingredient using high performance liquid chromatography (HPLC). FINDINGS: It was found that 60 (37%) of the anti-malarials tested did not meet the United States Pharmacopoeia (USP) specifications for the amount of active ingredients, with the suspect drugs either lacking the active ingredients or containing suboptimal quantities of the active ingredients. Quinine (46%) and SP formulations (39%) were among drugs that did not satisfy the tolerance limits published in USP monograms. A total of 78% of the suspect drugs were from private facilities, mostly low-level providers, such as patent medicine dealers (vendors). CONCLUSION: This study found that there was a high prevalence of poor quality drugs. The findings provide areas for public intervention to improve the quality of malaria treatment services. There should be enforced checks and regulation of drug supply management as well as stiffer penalties for people stocking substandard and counterfeit drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antimalarial Drug Quality in the Most Severely Malarious Parts of Africa – A Six Country Study
Bate, R., Coticelli, P., Tren, R., & Attaran, A. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002132 · Cited by 161 · cited 14×
“Researchers have evaluated the quality of CQ, quinine, SP, amodiaquine and proguanil formulations sold in the market in various parts of Africa, including eastern part of Congo DR and Kenya [10-12].”
BackgroundResultInfluential
Cited by
Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria
Achan, J., Talisuna, A. O., Erhart, A., Yeka, A., Tibenderana, J. K., Baliraine, F. N., Rosenthal, P. J., & D'Alessandro, U. (2011) · Malaria Journal · doi:10.1186/1475-2875-10-144 · Cited by 1,007
Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa
Nayyar, G. M., Breman, J. G., Newton, P. N., & Herrington, J. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(12)70064-6 · Cited by 410
The Lancet Nigeria Commission: investing in health and the future of the nation
Abubakar, I., Dalglish, S. L., Angell, B., Sanuade, O., Abimbola, S., Adamu, A. L., Adetifa, I. M. O., Colbourn, T., Ogunlesi, A. O., Onwujekwe, O., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02488-0 · Cited by 373
Self-citationOzawa, S., Evans, D. R., Bessias, S., Haynie, D. G., Yemeke, T. T., Laing, S. K., & Herrington, J. E. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.1662 · Cited by 356
COVID-19 pandemic and economic crisis: the Nigerian experience and structural causes
Ozili, P. K. (2021) · Journal of Economic and Administrative Sciences · doi:10.1108/jeas-05-2020-0074 · Cited by 340
Substandard and counterfeit medicines: a systematic review of the literature
Almuzaini, T., Choonara, I., & Sammons, H. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-002923 · Cited by 286
Substandard drugs: a potential crisis for public health
Johnston, A., & Holt, D. W. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12298 · Cited by 270
Alsan, M., Kammili, N., Lakshmi, J., Xing, A., Khan, A., Rani, M., Kolli, P., Relman, D. A., & Owens, D. K. (2018) · Emerging Infectious Diseases · doi:10.3201/eid2408.171030 · Cited by 31
Yakubu, R., Isa, A. M., Abubakar, I. J., Oreagba, I., & Awaisu, A. (2020) · Drug Safety in Developing Countries · doi:10.1016/b978-0-12-819837-7.00038-8 · Cited by 5
Metadata
- Authors
- Onwujekwe, O., Kaur, H., Dike, N., Shu, E., Uzochukwu, B., Hanson, K., Okoye, V., & Okonkwo, P.
- Venue
- Malaria Journal
- Published
- 2009-02-10
- Volume
- 8
- Issue
- 1
- Pages
- 22-22
- ISSN
- 1475-2875 (ISSN-L)
- OpenAlex
- W1980793725
- Cited by
- 119
- References
- 1
- FWCI
- 10.81
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.